425: Adagio Medical Receives CE Mark Approval for VT Cryoablation System, Plans European Commercial Launch

Adagio Medical's ultra-low temperature cryoablation system for ventricular tachycardia has received CE Mark approval and is set for immediate commercialization in select European centers.

Summary

• Adagio Medical has received CE Mark approval for its ultra-low temperature cryoablation (ULTC) system, specifically designed for treating monomorphic ventricular tachycardia (VT).
• The system includes an upgraded cryoablation console and the vCLAS ventricular cryoablation catheter.
• Commercial availability in select European centers is planned immediately, with a feature at the European Heart Rhythm Association (EHRA) conference in Berlin on April 7-9, 2024.
• The vCLAS catheter is a 9Fr bi-directional deflectable catheter with a 15mm ULTC ablation element, capable of creating lesions exceeding 10mm in width and depth.
• The CE Mark approval is based on the Cryocure-VT trial, which enrolled patients with monomorphic VT of both ischemic and non-ischemic origin at nine European and Canadian centers.
• Full results of the Cryocure-VT trial, including six-month follow-up data, will be presented at the EHRA conference on April 8, 2024.
• Adagio Medical is also planning additional US studies for the VT ablation system.

Sentiment

Score: 8

Explanation: The announcement is positive due to the CE Mark approval and planned commercialization, suggesting potential revenue generation and market expansion. The management's comments and trial results further support a positive outlook.

Positives

• CE Mark approval allows for immediate commercialization in select European centers.
• The vCLAS catheter is specifically designed for VT ablations, potentially improving outcomes.
• The ULTC technology may expand patient eligibility and enable earlier intervention for VT.
• The system simplifies hemodynamic management due to the absence of catheter irrigation.
• The use of cryogenic energy and associated cryoadhesion ensures catheter stability during ablation.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The commercial success of the VT cryoablation system depends on acceptance by clinicians and positive outcomes in real-world clinical practice.
• The proposed business combination with ARYA Sciences Acquisition Corp IV is subject to risks and uncertainties described in the Registration Statement on Form S-4.

Future Outlook

Adagio Medical plans to expand the use of ULTC technology in VT ablations and is conducting or planning additional US studies. The company expects to engage the European Electrophysiology community to maximize the potential of ULTC technology and patient benefit.

Management Comments

• 'We are encouraged by the commercial availability of the dedicated VT ablation system in our European centers, as it shows promise for patients with ventricular arrhythmias,' said Professor Dr. KR Julian Chun of Cardiovascular Center Bethanien (CCB) in Frankfurt, Germany.
• 'The current VT ablation practice has evolved around generic catheter tools available to the clinicians, with all associated trade-offs, limiting, to an extent, how broadly we offer ablations to a rather sick patient population with structural heart disease,' added Professor Dr. Boris Schmidt, an Electrophysiologist at CCB.
• 'We believe that the unique features and performance of ULTC will advance the field of VT ablations with outcomes warranting expansion of patient eligibility and earlier intervention,' said Olav Bergheim, President and CEO of Adagio Medical, Inc.

Industry Context

The announcement addresses the need for specialized tools in VT ablation, where generic catheters have been traditionally used. Adagio's dedicated VT ablation system aims to improve outcomes and expand treatment options for patients with ventricular arrhythmias.

Comparison to Industry Standards

• Conventional radiofrequency (RF) catheters are commonly used for both ventricular and atrial procedures, but Adagio's vCLAS catheter is specifically designed for VT ablations.
• The 9Fr, bi-directional deflectable vCLAS catheter features a 15-millimeter long ULTC ablation element, capable of creating lesions with titratable width and depth exceeding 10 millimeters, which may offer advantages over existing technologies.
• Companies like Medtronic, Abbott, and Boston Scientific offer RF ablation catheters, but Adagio's cryoablation approach provides a different energy modality with potential benefits in terms of catheter stability and hemodynamic management.

Stakeholder Impact

• Shareholders may benefit from the potential revenue generation and market expansion following CE Mark approval.
• Clinicians will have access to a dedicated VT ablation system, potentially improving patient outcomes.
• Patients with ventricular arrhythmias may benefit from the advanced ULTC technology and expanded treatment options.

Next Steps

• Immediate commercial availability of the VT cryoablation system in select European centers.
• Presentation of Cryocure-VT trial results at the EHRA conference on April 8, 2024.
• Ongoing or planned US studies for the VT ablation system.

Key Dates